Risk factors and clinical impact of klebsiella pneumoniae carbapenemase-producing K. pneumoniae

Infection Control and Hospital Epidemiology

Volumn 30, Issue 12, 2009, Pages 1180-1185

  Gasink, Leanne B ^a,b,c   Edelstein, Paul H ^a   Lautenbach, Ebbing ^a,b   Synnestvedt, Marie ^b   Fishman, Neil O ^a,b  

^a School of Veterinary Medicine   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CARBAPENEM DERIVATIVE; CARBAPENEMASE; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; MEROPENEM; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DRUG UTILIZATION; FEMALE; HUMAN; INFECTION RISK; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONHUMAN; RISK ASSESSMENT; RISK FACTOR;

BACTERIAL PROTEINS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CASE-CONTROL STUDIES; COHORT STUDIES; CROSS INFECTION; FEMALE; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; RISK FACTORS;

EID: 73449096797     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/648451     Document Type: Article

References (35)

1. Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 2003;289:885-888.
2. Streit JM, Jones RN, Sader HS, Fritsche TR. Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). Int J Antimicrob Agents 2004;24:111-118.
3. Falagas ME, Bliziotis IA. Pandrug-resistant gram-negative bacteria: the dawn of the post-antibiotic era? Int J Antimicrob Agents 2007;29:630-636.
4. National Nosocomial Infections Surveillance S. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32:470-485.
5. MacKenzie FM, Forbes KJ, Dorai-John T, Amyes SG, Gould IM. Emergence of a carbapenem-resistant Klebsiella pneumoniae. Lancet 1997;350:783.
6. Bradford PA, Bratu S, Urban C, et al. Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City. Clin Infect Dis 2004;39:55-60.
7. Leavitt A, Navon-Venezia S, Chmelnitsky I, Schwaber MJ, Carmeli Y. Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital. Antimicrob Agents Chemother 2007;51:3026-3029.
8. Bratu S, Mooty M, Nichani S, et al. Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection. Antimicrob Agents Chemother 2005;49:3018-3020.
9. Pope J, Adams J, Doi Y, Szabo D, Paterson DL. KPC type beta-lactamase, rural Pennsylvania. Emerg Infect Dis 2006;12:1613-1614.
10. Villegas MV, Lolans K, Correa A, et al. First detection of the plasmidmediated class A carbapenemase KPC-2 in clinical isolates of Klebsiella pneumoniae from South America. Antimicrob Agents Chemother 2006;50:2880-2882.
11. Zhang R, Zhou HW, Cai JC, Chen GX. Plasmid-mediated carbapenemhydrolysing beta-lactamase KPC-2 in carbapenem-resistant Serratia marcescens isolates from Hangzhou, China. J Antimicrob Chemother 2007;59:574-576.
12. Tenover FC, Kalsi RK, Williams PP, et al. Carbapenem resistance in Klebsiella pneumoniae not detected by automated susceptibility testing. Emerg Infect Dis 2006;12:1209-1213.
13. Bratu S, Landman D, Haag R, et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch Intern Med 2005;165:1430-1435.
14. Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, Schwartz D, Leavitt A, Carmeli Y. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effectof acquisition onmortality. Antimicrob Agents Chemother 2008;52:1028-1033.
15. Falagas ME, Rafailidis PI, Kofteridis D, et al. Risk factors of carbapenemresistant Klebsiella pneumoniae infections: a matched case control study. J Antimicrob Chemother 2007;60:1124-1130.
16. Kwak YG, Choi SH, Choo EJ, et al. Risk factors for the acquisition of carbapenem-resistant Klebsiella pneumoniae among hospitalized patients. Microb Drug Resist 2005;11:165-169.
17. Patel G, Huprikar S, Factor S, Jenkins S, Calfee D. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008;29:1099-1106.
18. McGettigan SE, Adreaecchio K, Edelstein PH. Specificity of ertapenem susceptibility screening for the detection of Klebsiella pneumoniae carbapenemases (KPC). J Clin Microbiol 2009;47:785-786.
19. Lomaestro BM, Tobin EH, Shang W, Gootz T. The spread of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae to upstate New York. Clin Infect Dis 2006;43:e26-e28.
20. Anderson KF, Lonsway DR, Rasheed JK, et al. Evaluation of methods to identify the Klebsiella pneumoniae carbapenemase in Enterobacteriaceae. J Clin Microbiol 2007;45:2723-2725.
21. Harris AD, Karchmer TB, Carmeli Y, Samore MH. Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review. Clin Infect Dis 2001;32:1055-1061.
22. Gasink LB, Fishman NO, Nachamkin I, Bilker WB, Lautenbach E. Risk factors for and impact of infection or colonization with aztreonamresistant Pseudomonas aeruginosa. Infect Control Hosp Epidemiol 2007;28:1175-1180.
23. 3M Health Information Systems. All-patient refined diagnosis related groups (APR-DRGs) methodology overview, version 20. Wallingford, CT: 3M Health Information Systems; 2003.
24. Mendes RE, Bell JM, Turnidge JD, et al. Carbapenem-resistant isolates of Klebsiella pneumoniae in China and detection of a conjugative plasmid (blaKPC-2 plus qnrB4) and a blaIMP-4 gene. Antimicrob Agents Chemother 2008;52:798-799.
25. Endimiani A, Carias LL, Hujer AM, et al. Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States. Antimicrob Agents Chemother 2008;52:2680-2682.
26. Rice LB, Carias LL, Hutton RA, Rudin SD, Endimiani A, Bonomo RA. The KQ element, a complex genetic region conferring transferable resistance to carbapenems, aminoglycosides, and fluoroquinolones in Klebsiella pneumoniae. Antimicrob Agents Chemother 2008;52:3427-3429.
27. Naas T, Cuzon G, Villegas MV, Lartigue MF, Quinn JP, Nordmann P. Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene. Antimicrob Agents Chemother 2008;52:1257-1263.
28. Linder JA, Huang ES, Steinman MA, Gonzales R, Stafford RS. Fluoroquinolone prescribing in the United States: 1995 to 2002. Am J Med 2005;118:259-268.
29. Gould CV, Fishman NO, Nachamkin I, Lautenbach E. Chloramphenicol resistance in vancomycin-resistant enterococcal bacteremia: impact of prior fluoroquinolone use? Infect Control Hosp Epidemiol 2004;25:138-145.
30. Wiener J, Quinn JP, Bradford PA, et al. Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. JAMA 1999;281:517-523.
31. Lautenbach E, Weiner MG, Nachamkin I, Bilker WB, Sheridan A, Fishman NO. Imipenem resistance among Pseudomonas aeruginosa: risk factors for emergence and impact of resistance on clinical and economic outcomes. Infect Control Hosp Epidemiol 2006;27:893-900.
32. Paramythiotou E, Lucet JC, Timsit JF, et al. Acquisition of multidrugresistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity. Clin Infect Dis 2004;38:670-677.
33. Jacoby GA. Mechanisms of resistance to quinolones. Clin Infect Dis 2005;41(Suppl 2):S120-S126.
34. Woodford N, Tierno PM Jr, Young K, et al. Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A beta-lactamase, KPC-3, in a New York Medical Center. Antimicrob Agents Chemother 2004;48:4793-4799.
35. Ahmad M, Urban C, Mariano N, et al. Clinical characteristics and molecular epidemiology associated with imipenem-resistant Klebsiella pneumoniae. Clin Infect Dis 1999;29:352-355.